Immuno-PET identifies the myeloid compartment as a key contributor to the outcome of the antitumor response under PD-1 blockade
暂无分享,去创建一个
R. Weinberg | C. Paweletz | G. Freeman | H. Ploegh | M. I. Barrasa | A. Sharpe | Yun Zhang | Anushka Dongre | A. Aref | M. LaFleur | M. Rashidian | Thao H. Nguyen | Xia Bu | V. Verschoor | C. Lau | Thao H Nguyen | Stephen C. Kolifrath | G. Freeman | Vincent L. Verschoor
[1] E. Nduom,et al. Biomarkers for immunotherapy for treatment of glioblastoma , 2020, Journal for immunotherapy of cancer.
[2] P. Allavena,et al. Current Strategies to Target Tumor-Associated-Macrophages to Improve Anti-Tumor Immune Responses , 2019, Cells.
[3] T. Lawrence,et al. Targeting STAT3 and STAT5 in Tumor-Associated Immune Cells to Improve Immunotherapy , 2019, Cancers.
[4] Evan W. Newell,et al. High-Dimensional Analysis Delineates Myeloid and Lymphoid Compartment Remodeling during Successful Immune-Checkpoint Cancer Therapy , 2018, Cell.
[5] Roger D Kamm,et al. 3D microfluidic ex vivo culture of organotypic tumor spheroids to model immune checkpoint blockade. , 2018, Lab on a chip.
[6] Jennifer L. Guerriero. Macrophages: The Road Less Traveled, Changing Anticancer Therapy. , 2018, Trends in molecular medicine.
[7] Paul Hoffman,et al. Integrating single-cell transcriptomic data across different conditions, technologies, and species , 2018, Nature Biotechnology.
[8] G. Longmore,et al. SNAIL1 action in tumor cells influences macrophage polarization and metastasis in breast cancer through altered GM-CSF secretion , 2018, Oncogenesis.
[9] Zhi Wei,et al. Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids. , 2018, Cancer discovery.
[10] Yan Zhang,et al. Upregulation of PD‐L1 by SPP1 mediates macrophage polarization and facilitates immune escape in lung adenocarcinoma , 2017, Experimental cell research.
[11] R. Weinberg,et al. Predicting the response to CTLA-4 blockade by longitudinal noninvasive monitoring of CD8 T cells , 2017, The Journal of experimental medicine.
[12] J. Thiery,et al. New insights into the role of EMT in tumor immune escape , 2017, Molecular oncology.
[13] R. Weinberg,et al. Epithelial-to-Mesenchymal Transition Contributes to Immunosuppression in Breast Carcinomas. , 2017, Cancer research.
[14] Yoshiyuki Hizukuri,et al. Guanylate-binding protein 5 is a marker of interferon-γ-induced classically activated macrophages , 2016, Clinical & translational immunology.
[15] Matheus C. Bürger,et al. Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy , 2016, Nature.
[16] G. Freeman,et al. Coinhibitory Pathways in Immunotherapy for Cancer. , 2016, Annual review of immunology.
[17] Steven H. Liang,et al. Enzyme-Mediated Modification of Single-Domain Antibodies for Imaging Modalities with Different Characteristics. , 2016, Angewandte Chemie.
[18] A. Ribas,et al. An Effective Immuno-PET Imaging Method to Monitor CD8-Dependent Responses to Immunotherapy. , 2016, Cancer research.
[19] R. Weissleder,et al. Use of 18F-2-Fluorodeoxyglucose to Label Antibody Fragments for Immuno-Positron Emission Tomography of Pancreatic Cancer , 2015, ACS central science.
[20] Ralph Weissleder,et al. Noninvasive imaging of immune responses , 2015, Proceedings of the National Academy of Sciences.
[21] D. Fearon,et al. T cell exclusion, immune privilege, and the tumor microenvironment , 2015, Science.
[22] R. Ahmed,et al. Reinvigorating Exhausted T Cells by Blockade of the PD-1 Pathway. , 2015, Forum on immunopathological diseases and therapeutics.
[23] W. Huber,et al. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 , 2014, Genome Biology.
[24] R. Emerson,et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance , 2014, Nature.
[25] Jeffrey W Pollard,et al. Tumor-associated macrophages: from mechanisms to therapy. , 2014, Immunity.
[26] S. Gordon,et al. The M1 and M2 paradigm of macrophage activation: time for reassessment , 2014, F1000prime reports.
[27] H. Koblish,et al. Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8+ T cells directly within the tumor microenvironment , 2014, Journal of Immunotherapy for Cancer.
[28] Wei Shi,et al. featureCounts: an efficient general purpose program for assigning sequence reads to genomic features , 2013, Bioinform..
[29] J. Wolchok,et al. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma , 2013, The Journal of experimental medicine.
[30] I. Kalomenidis,et al. Beneficial Impact of CCL2 and CCL12 Neutralization on Experimental Malignant Pleural Effusion , 2013, PloS one.
[31] Thomas R. Gingeras,et al. STAR: ultrafast universal RNA-seq aligner , 2013, Bioinform..
[32] Douglas Hanahan,et al. Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment Prospects and Obstacles for Therapeutic Targeting of Function-enabling Stromal Cell Types , 2022 .
[33] Peter Vogel,et al. Microenvironment and Immunology Immune Inhibitory Molecules Lag-3 and Pd-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape , 2022 .
[34] M. Sporn,et al. Tumor-infiltrating myeloid cells induce tumor cell resistance to cytotoxic T cells in mice. , 2011, The Journal of clinical investigation.
[35] M. Nishimura,et al. CD8+ tumor-infiltrating lymphocytes predict favorable prognosis in malignant pleural mesothelioma after resection , 2010, Cancer Immunology, Immunotherapy.
[36] P. Jurek,et al. Conjugation and radiolabeling of monoclonal antibodies with zirconium-89 for PET imaging using the bifunctional chelate p-isothiocyanatobenzyl-desferrioxamine , 2010, Nature Protocols.
[37] P. Sinha,et al. Myeloid-Derived Suppressor Cells: Linking Inflammation and Cancer 1 , 2009, The Journal of Immunology.
[38] A. Gemma,et al. Predominant infiltration of macrophages and CD8+ T Cells in cancer nests is a significant predictor of survival in stage IV nonsmall cell lung cancer , 2008, Cancer.
[39] P. Allavena,et al. The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages. , 2008, Critical reviews in oncology/hematology.
[40] Loise M. Francisco,et al. PD-1 and its ligands in T-cell immunity. , 2007, Current opinion in immunology.
[41] Gerd Ritter,et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[42] S. Segal,et al. CD11b+/Gr-1+ Immature Myeloid Cells Mediate Suppression of T Cells in Mice Bearing Tumors of IL-1β-Secreting Cells1 , 2005, The Journal of Immunology.
[43] R. Proia,et al. The S1P-analog FTY720 differentially modulates T-cell homing via HEV: T-cell-expressed S1P1 amplifies integrin activation in peripheral lymph nodes but not in Peyer patches. , 2005, Blood.
[44] R. Gibbs,et al. Genomic segmental polymorphisms in inbred mouse strains , 2004, Nature Genetics.
[45] W. Kuziel,et al. CC Chemokine Ligand 3 (CCL3) Regulates CD8+-T-Cell Effector Function and Migration following Viral Infection , 2003, Journal of Virology.
[46] S. Goerdt,et al. Alternatively Activated Macrophages Differentially Express Fibronectin and Its Splice Variants and the Extracellular Matrix Protein βIG‐H3 , 2001, Scandinavian journal of immunology.
[47] M. Bally,et al. The role of tumor-associated macrophages in the delivery of liposomal doxorubicin to solid murine fibrosarcoma tumors. , 1997, The Journal of pharmacology and experimental therapeutics.
[48] Mark M. Davis,et al. T-cell antigen receptor genes and T-cell recognition , 1988, Nature.
[49] A. Paulen. A time for reassessment. , 1986, Cancer nursing.
[50] L. Hood,et al. The human t cell antigen receptor is encoded by variable, diversity, and joining gene segments that rearrange to generate a complete V gene , 1984, Cell.